Medical diagnostic firm Biomerica's Q1 revenue falls on lower retail activity

Reuters
10/15
Medical diagnostic firm Biomerica's Q1 revenue falls on lower retail activity

Overview

  • Biomerica fiscal Q1 revenue fell to $1.4 mln from $1.8 mln, reflecting reduced retail activity

  • Gross margin improved to 31% from 16%, driven by higher-margin product mix

  • Operating expenses decreased to $1.5 mln, highlighting cost discipline

Outlook

  • Biomerica did not provide specific financial guidance for future periods

Result Drivers

  • HIGHER-MARGIN PRODUCT MIX - Improved gross margin driven by contribution from higher-margin products

  • COST REDUCTION - Decline in operating expenses due to focus on cost reduction and operational efficiency

  • NON-RECURRING TAX CREDIT - Net profit aided by non-recurring tax credit

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

$1.40 mln

Q1 Net Income

$0.0

Q1 Gross Margin

31%

Q1 Operating Expenses

$1.50 mln

Q1 Operating Income

-$1.10 mln

Press Release: ID:nGNXcc5s9M

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10